Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV8102 and Rabies Vaccine in Healthy Adults
NCT02238756Phase 1Completed
- Sponsor
- CureVac
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CV8102 in rabies (3 arms), sponsored by CureVac. Primary endpoint: Number of subjects with serious and non serious adverse events up to 12 months. Started Sep 2014; status: completed.
02
Drugs
CV8102
03
Conditions
rabies
Beyond the preview
Go deeper on NCT02238756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238756.